SCHEMBL24700587

SCHEMBL24700587

CN1CCN(C2CCN(C(=O)OC(C)(C)C)C(C)(C)C2)CC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.36
CHRM1 P11229 1/20 0.36
CHRM3 P20309 1/20 0.36
EPHX2 P34913 1/20 0.36
EPHX1 P07099 1/20 0.35
PREP P48147 2/20 0.33
HPGD P15428 1/20 0.33
ACACB O00763 1/20 0.33
ACACA Q13085 1/20 0.33
HRH3 Q9Y5N1 1/20 0.32
PTPN2 P17706 1/20 0.32
PTPN1 P18031 1/20 0.32
PTPN6 P29350 1/20 0.32
RECQL P46063 1/20 0.32
CTSK P43235 1/20 0.32
HSD11B1 P28845 1/20 0.32
USP2 O75604 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
L3MBTL3 Q96JM7 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24700163 0.88 HPGD (0.43) CHRM2CHRM1CHRM3EPHX2EPHX1
SCHEMBL30761098 0.85 USP2 (0.47) CHRM2CHRM1CHRM3EPHX2EPHX1
SCHEMBL24700588 0.84 CHRM1 (0.35) CHRM2CHRM1CHRM3EPHX2EPHX1
SCHEMBL29156244 0.82 CHRM2 (0.35) CHRM2CHRM1CHRM3EPHX2EPHX1
SCHEMBL23124155 0.81 GPR119 (0.37) CHRM2CHRM1CHRM3EPHX2EPHX1
SCHEMBL29156252 0.79 RECQL (0.50) EPHX2PREPHPGDHRH3PTPN2
SCHEMBL24700396 0.78 NAMPT (0.45)
SCHEMBL5140938 0.77 CHRM2 (0.45) CHRM2CHRM1CHRM3EPHX2EPHX1
SCHEMBL23825249 0.77 CHRM2 (0.41) CHRM2CHRM1CHRM3EPHX2EPHX1
SCHEMBL4987189 0.77 HPGD (0.51) EPHX1HPGDHRH3PTPN2PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220380314-A1 SUBSTITUTED, SATURATED AND UNSATURATED N-HETEROCYCLIC CARBOXAMIDES AND RELATED COMPOUNDS FOR THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GBA2, CLN6 CHRM2 3991/4885CHRM1 4097/4885CHRM3 4160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.